Skip to main content
ADIM logo

ADIM — Investor Relations & Filings

Ticker · 4142 ISIN · TW0004142005 LEI · 549300M5TV8YGVXU1827 TW Manufacturing
Open in API
Filings indexed 1,804 across all filing types
Latest filing 2016-11-28 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 4142

About ADIM

http://www.adimmune.com.tw/

ADIMMUNE CORPORATION, established in 1965, specializes in the research, development, and large-scale manufacturing of human vaccines and biologics. The company is a primary supplier of seasonal influenza and tetanus vaccines, maintaining production facilities that adhere to PIC/S GMP, US FDA, and EU standards. Its operations encompass the full product lifecycle, from initial R&D to commercial distribution. In addition to its proprietary vaccine portfolio, the company provides Contract Development and Manufacturing Organization (CDMO) services, supporting collaborative development and global supply chains. Recognized for its technical expertise in viral and bacterial vaccine production, the organization focuses on delivering high-quality immunization solutions to international markets while leveraging its history as a pioneering vaccine laboratory.

Recent filings

Filing Released Lang Actions
105年第3季資產負債表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated balance sheet with detailed financial data for multiple periods, including specific dates such as 105年09月30日 (which corresponds to the third quarter of the fiscal year 2016 in the Taiwanese calendar). The presence of detailed asset, liability, and equity figures indicates this is a substantive financial report rather than a brief announcement or certification. The document length is 3869 characters, which is relatively short but contains actual financial statements. The content corresponds to an Interim / Quarterly Report (IR) because it covers a period shorter than a full fiscal year (third quarter) and includes comprehensive financial data. There is no indication that this is an Annual Report (10-K) or a simple announcement. Therefore, the classification is Interim / Quarterly Report (IR). Q3 2016
2016-11-28 Chinese
說明媒體報導
Regulatory Filings Classification · 95% confidence The document is a short announcement (775 characters) from a company (國光生物科技股份有限公司) explaining and clarifying a media report about the company's business prospects and growth expectations. It references a media report and states that any concrete progress will be disclosed according to regulations. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, or other specific report content. The document is essentially a regulatory announcement clarifying media coverage, fitting the description of a Regulatory Filing (RNS). It is not a full report, presentation, or financial statement, and it is not a report publication announcement since it does not mention any report being attached or published.
2016-11-23 Chinese
105年11月法人說明會簡報 — 414220161121E001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed presentation from November 2016 about a vaccine company, including extensive information on management, strategy, products, certifications, and market expansion plans. It contains forward-looking statements, executive summaries, leadership profiles, product pipelines, and growth strategies. The content is structured as a presentation with slides and images (omitted here), focusing on financial performance, business outlook, and company strategy. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. It is not a regulatory filing, nor a voting result or legal proceeding. The document fits the description of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position.
2016-11-21 Chinese
105年11月法人說明會簡報 — 414220161121M001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed presentation about the company's profile, management team, product portfolio, market strategy, and future growth plans. It includes forward-looking statements, company history, certifications, clinical trials, and product development pipeline. The content is structured as a corporate presentation with slides and images (omitted here) and is intended for investors or stakeholders to understand the company's business and strategy. There are no financial statements, audit opinions, voting results, or regulatory filings. The document is not a transcript of a call, nor an announcement of a report. It is a comprehensive investor presentation focusing on financials, strategy, and market position, matching the definition of an Investor Presentation (IP). The document length is substantial (12,281 characters), indicating it is the full presentation, not just an announcement.
2016-11-21 Chinese
105年11月法人說明會簡報 — 414220161102E001.ppt
Investor Presentation Classification · 96% confidence The document is a slide-based presentation dated November 2016 featuring forward-looking disclaimers, corporate overview, management team bios, business strategy, market positioning, product pipeline, capacity and growth strategy. It is clearly presented as an investor deck rather than an official financial report or regulatory filing. There are no formal financial statements or voting results, nor is it a certification or press release of earnings. It matches the description of an Investor Presentation (IP).
2016-11-21 English
105年11月法人說明會簡報 — 414220161102M001.ppt
Investor Presentation Classification · 92% confidence The document is a multi‐slide corporate presentation containing forward‐looking disclaimers, company overview, management team bios, strategy, product pipeline, and market positioning. It is a detailed slide deck aimed at investors rather than a formal regulatory filing like an annual report, earnings release, or proxy statement. Therefore, it fits the definition of an Investor Presentation (IP).
2016-11-21 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.